{"protocolSection":{"identificationModule":{"nctId":"NCT04995757","orgStudyIdInfo":{"id":"2016-GATOR-01-A"},"organization":{"fullName":"Changhai Hospital","class":"OTHER"},"briefTitle":"CAPTURE Registration Trial of the Thrombectomy System for the Treatment of Acute Ischemic Stroke.","officialTitle":"Prospective, Randomized, Controlled, Open Label, Single Blinded, All China, Multi-Center, Registration Trial of the Thrombectomy System for the Treatment of Acute Ischemic Stroke."},"statusModule":{"statusVerifiedDate":"2021-07","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2018-03-21","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2020-07-05","type":"ACTUAL"},"completionDateStruct":{"date":"2020-09-22","type":"ACTUAL"},"studyFirstSubmitDate":"2021-07-30","studyFirstSubmitQcDate":"2021-07-30","studyFirstPostDateStruct":{"date":"2021-08-09","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-07-30","lastUpdatePostDateStruct":{"date":"2021-08-09","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Jian-min Liu","investigatorTitle":"Professor","investigatorAffiliation":"Changhai Hospital"},"leadSponsor":{"name":"Changhai Hospital","class":"OTHER"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"As this will be a pre-market registration trial, in which devices will be used in accordance with appropriately labeled indications, pre-study notifications and approval requests will be addressed with CFDA. All trial results will be shared with CFDA."},"conditionsModule":{"conditions":["Acute Ischemic Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","whoMasked":["PARTICIPANT"]}},"enrollmentInfo":{"count":239,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"MicroPort NeuroTech Stentretriever","type":"EXPERIMENTAL","interventionNames":["Device: Stent Retriever"]},{"label":"Solitaire FR","type":"ACTIVE_COMPARATOR","interventionNames":["Device: Stent Retriever"]}],"interventions":[{"type":"DEVICE","name":"Stent Retriever","description":"Stent Retriever for acute ischemic stroke","armGroupLabels":["MicroPort NeuroTech Stentretriever","Solitaire FR"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Successful Recanalization Rate","description":"Defined as modified treatment in cerebral infarction (mTICI) ≥ 2b","timeFrame":"immediate post-thrombectomy (t-0) and no later than 3 hours' post-procedure (t-3)"}],"secondaryOutcomes":[{"measure":"mRS at D90","description":"The modified Rankin Scale (mRS), a combined clinical/functionality and secondary safety endpoint, reflects the degree of disability or dependence in activities of daily living among treated patients. Though listed and classified separately, in multiple publications, as a functionality or clinical endpoint and because of its prominent and unique value in stroke trials, mRS should be considered first among key safety parameters in subjects who complete the 90-day evaluation.\n\nA successful endpoint will be defined as follows: \"at 90± 14 days' post-treatment, the frequency of mRS scores ≤2 or a post-treatment decrease in mRS score of ≥2, relative to the baseline determination\". Patients who die, between thrombectomy initiation and 90-Days, will be given an mRS value of 6 in this analysis.","timeFrame":"90± 14 days' post-treatment"},{"measure":"Time from puncture to mTICI≥2b","description":"Time from puncture to mTICI≥2b","timeFrame":"immediate post-thrombectomy (t-0)"},{"measure":"The NIHSS score at 30H post-treatment","description":"The NIHSS score at 30H post-treatment","timeFrame":"30± 6 hours' post-treatment"},{"measure":"Symptomatic intracranial hemorrhage(sICH) within 30H post-treatment","description":"Any intracranial hemorrhage judged by CT(or MRI) with neurological symptoms","timeFrame":"30±6 hours' post-treatment"},{"measure":"Death within 90D post-treatment","description":"Any cause death within 90D post-treatment","timeFrame":"90± 14 days' post-treatment"},{"measure":"AE/SAE within 90D post-treatment","description":"Any cause AE/SAEs within 90D post-treatment","timeFrame":"90± 14 days' post-treatment"},{"measure":"Stentretriever/procedure/stroke related AE/SAEs within 90D post-treatment","description":"Stentretriever/procedure/stroke related AE/SAEs within 90D post-treatment","timeFrame":"90± 14 days' post-treatment"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject must demonstrate clinical signs and symptoms that are attributable to the targeted lesion and are consistent with the diagnosis of acute ischemic stroke (AIS), as confirmed by a neuroradiologist (or equivalent expert), using appropriate imaging. Arterial occlusion of ICA, MCA-M1 or MCA-M2.\n* Female or male subject, who, at the time of consenting, is aged between 18 and 80 years, inclusive.\n* Within 6 hours of stroke symptom onset, subject must have undergone treatment initiation (vascular access through puncture or cut down).\n* Signed Informed Consent Form (ICF) completed by subject or subject's legal representative.\n\nExclusion Criteria:\n\n* 1. Functional dependence prior to stroke onset, defined as a pre-stroke modified Rankin Scale (mRS) score of ≥2.\n* 2. Subject's baseline NIHSS score \\<2 or \\>25.\n* 3. History of severe head injury within past 90 days with residual neurological deficit, as determined by medical history.\n* 4. Pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations, e.g. dementia with prescribed anti-cholinesterase inhibitor.\n* 5. Seizures at stroke onset if it makes the diagnosis of stroke doubtful and precludes obtaining an accurate baseline NIHSS assessment.\n* 6. Subject has a known hemorrhagic diathesis, coagulation factor deficiency; or, is on oral anticoagulant therapy and has an International Normalized Ratio (INR) \\>3.\n* 7. Subject's baseline platelet count is \\<30\\*10\\^9/L.\n* 8. Subject's baseline glucose is \\<50 mg/dL (2.78 mmol/L) or \\>400 mg/dL (22.2 mmol/L).\n* 9. Renal failure, as defined by a serum creatinine \\>3.0 mg/dL (264 µmol/L) \\[NOTE: subjects on renal dialysis may be treated regardless of serum creatinine levels\\].\n* 10. Severe, sustained hypertension (SBP \\> 185 mm Hg or DBP \\> 110 mmHg) \\[if the blood pressure can be successfully reduced and maintained at the acceptable level, using medication, the patient can be enrolled\\].\n* 11. Subject has known allergy or contraindication to one or more of the following: anti-platelet drugs; contrast dye; and/or, local or general anesthesia.\n* 12. Subject has known allergy to nickel, cobalt chromium, tungsten, platinum or other metal that may be a component of a required medical device needed for treatment.\n* 13. Subject is generally unsuitable for endovascular intervention or anesthesia.\n* 14. Subject has had major surgery within the previous 30 days\n* 15. Subject is an active participant in another drug or device treatment trial for any disease state; or, subject is expected to start participation in another drug or device trial while enrolled in this protocol.\n* 16. Subject currently has infective endocarditis or other severe, active bacterial infection.\n* 17. Subject's life expectancy is less than 6 months.\n* 18. Female of childbearing potential who is known to be pregnant and/or lactating or who has a positive pregnancy test on admission.\n\nImaging Exclusion Criteria:\n\n* 19. Subject has CT scan or MRI evidence of the following:\n\n  * Significant mass effect with midline shift.\n  * Evidence of intracranial tumor, except small meningioma.\n  * Evidence of intracranial hemorrhage.\n  * Evidence of internal carotid artery flow limiting dissection.\n  * Suspected cerebral vasculitis.\n  * Suspected aortic dissection.\n  * Occlusions in multiple vascular territories (e.g., bilateral anterior circulation, or anterior/posterior circulation) or clinical evidence of bilateral strokes or strokes in multiple territories.\n* 20. The presence of a large completed territorial infarction by non-contrast CT (NCCT), defined as an Alberta Stroke Program Early CT Score (ASPECTS) ≤5.\n* 21. Other unusual morphology or lesion that might interfere with device use, including but not limited to the following:\n\n  * Carotid dissection\n  * Vasculitis\n  * Aortic dissection\n  * Aneurysm\n  * No transfemoral or alternative access, such as:\n\n    1. Severe intracranial tortuosity\n    2. Severe intracranial vasospasm, unresponsive to pharmacotherapy.\n    3. Other anatomical or clinical conditions contraindicated for access.\n* 22. Anterior circulation strokes involving \\> 1/3 of the MCA territory, as determined by hypo-density on the baseline non-contrast CT, or low CBV on CT Perfusion imaging, or restricted diffusion on DWI images.\n* 23. Thrombotic occlusion in the posterior circulation arteries (vertebral, basilar, etc.)\n* 24. Intracranial stent implanted in the same vascular territory that would preclude the safe deployment/removal of the thrombectomy device.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Changhai Hospital","city":"Shanghai","state":"Shanghai City","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]}},"hasResults":false}